MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Results of Operations and Financial ConditionItem 2.02
Results of Operations and Financial Condition
On July 26, 2017, MiMedx Group, Inc. (the “Company”) issued a press release announcing its financial results for the period ended June 30, 2017 and certain other matters.The release also announced that executives of the Company would discuss these results with investors on a conference call broadcast via the Company’s website located at www.mimedx.com and provided access information, date and time for the conference call. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Information contained on the Company's website is not incorporated by reference into this Current Report on Form 8-K.
The information provided to Item 2.02 of this Form 8-K is to be considered “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
|
Item 9.01 |
Financial Statements and Exhibits |
|
Exhibit No. |
Description |
|
99.1 |
MiMedx Group, Inc. Press Release, dated July 26, 2017 |
MIMEDX GROUP, INC. ExhibitEX-99.1 2 mdxg-2017727xex991.htm EXHIBIT 99.1 Exhibit EXHIBIT 99.1PRESS RELEASE Contact: Michael SenkenPhone: (770) 651-9100MIMEDX ANNOUNCES RECORD RESULTS FOR THE SECOND QUARTER OF 2017 AND RAISES FULL YEAR REVENUE GUIDANCECOMPANY RECORDS 33% REVENUE GROWTH AND A 309% INCREASE IN NET INCOME OVER Q2 2016Marietta,…To view the full exhibit click here
About MIMEDX GROUP, INC. (NASDAQ:MDXG)
MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.
